Bionexus Gene Lab CORP 8-K filings

NASDAQ

5 Jul 2024

BGLC

8-K/A: BioNexus Gene Lab Corp. Amends CEO and CFO Service Contract, Increases Monthly Salary to $35,000

BioNexus Gene Lab Corp. has amended its service contract with Su-Leng Tan Lee, increasing his monthly base salary to $35,000 and providing back pay for his roles as CEO and Acting CFO.

NASDAQ

9 May 2024

BGLC

Bionexus Gene Lab CORP

8-K: BioNexus Gene Lab Corp. Granted Second Extension to Regain Nasdaq Compliance

BioNexus Gene Lab Corp. has received a second 180-day extension from Nasdaq to regain compliance with the minimum bid price rule.

NASDAQ

18 Apr 2024

BGLC

Bionexus Gene Lab CORP

8-K: BioNexus Gene Lab Corp. Invests $250k in Ascension Innovation to Boost AI in Healthcare

BioNexus Gene Lab Corp. has made a strategic investment of approximately $250,000 in Ascension Innovation to advance digital health innovation through AI adoption.

NASDAQ

1 Apr 2024

BGLC

Bionexus Gene Lab CORP

8-K: BioNexus Gene Lab Corp. Announces Major Board and Management Overhaul

BioNexus Gene Lab Corp. has replaced its entire board of directors and appointed a new CEO following a shareholder vote.